Baird Starts Myovant Sciences Ltd. (MYOV) at Outperform
Get Alerts MYOV Hot Sheet
Rating Summary:
4 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Baird initiates coverage on Myovant Sciences Ltd. (NYSE: MYOV) with a Outperform rating and a price target of $20.00.
Analyst Brian Skorney commented, "Myovant's lead asset, relugolix, in-licensed from Takeda in April, draws similarities to AbbVie's/Neurocrine's potential blockbuster, elagolix. Relugolix has a few potential advantages over existing therapies, a validated mechanism of action, and eyes set on three significant market opportunities. With the drug entering global Phase 3 trials in the next few months and Japanese Phase 3 data expected in 2H17 from licensor Takeda, 2017 could be a pivotal year for Myovant. We are initiating at a $20 price target."
For an analyst ratings summary and ratings history on Myovant Sciences Ltd. click here. For more ratings news on Myovant Sciences Ltd. click here.
Shares of Myovant Sciences Ltd. closed at $11.25 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TD Cowen Starts Grindr (GRND) at Buy
- Walgreens Boosts Alliance (WBA) PT Lowered to $19 at Jefferies
- AO World Plc. (AO/:LN) PT Raised to GBP1.25 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, New CoverageRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!